12-110914200-C-G
Variant summary
Our verdict is Likely pathogenic. Variant got 6 ACMG points: 6P and 0B. PM1PM2PP3PP5
The ENST00000228841.15(MYL2):c.260G>C(p.Gly87Ala) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G87E) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000228841.15 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 6 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYL2 | NM_000432.4 | c.260G>C | p.Gly87Ala | missense_variant | 4/7 | ENST00000228841.15 | NP_000423.2 | |
MYL2 | NM_001406745.1 | c.218G>C | p.Gly73Ala | missense_variant | 3/6 | NP_001393674.1 | ||
MYL2 | NM_001406916.1 | c.203G>C | p.Gly68Ala | missense_variant | 4/7 | NP_001393845.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYL2 | ENST00000228841.15 | c.260G>C | p.Gly87Ala | missense_variant | 4/7 | 1 | NM_000432.4 | ENSP00000228841 | P1 | |
MYL2 | ENST00000548438.1 | c.218G>C | p.Gly73Ala | missense_variant | 3/6 | 3 | ENSP00000447154 | |||
MYL2 | ENST00000663220.1 | c.203G>C | p.Gly68Ala | missense_variant | 4/7 | ENSP00000499568 | ||||
MYL2 | ENST00000549029.1 | n.91G>C | non_coding_transcript_exon_variant | 1/2 | 2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hypertrophic cardiomyopathy Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Feb 16, 2017 | The p.Gly87Ala variant in MYL2 has been identified by our laboratory in 2 indivi duals with HCM and segregated with disease in 4 affected relatives. It has not b een identified in large population studies. This variant was predicted to be pat hogenic using a computational tool clinically validated by our laboratory. This tool's pathogenic prediction is estimated to be correct 94% of the time (Jordan 2011). In summary, although additional studies are required to fully establish i ts clinical significance, the p.Gly87Ala variant is likely pathogenic. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Oct 11, 2019 | Reported in association with HCM, though patient-specific clinical and family data were not provided (Lopes et al., 2015; Walsh et al., 2017; Norrish et al., 2019); Not observed in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; This variant is associated with the following publications: (PMID: 25351510, 27532257, 31006259) - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 25, 2020 | The p.G87A variant (also known as c.260G>C), located in coding exon 4 of the MYL2 gene, results from a G to C substitution at nucleotide position 260. The glycine at codon 87 is replaced by alanine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. This alteration has been reported in multiple hypertrophic cardiomyopathy (HCM) cohorts; however, clinical details were limited (Lopes LR et al. Heart, 2015 Feb;101:294-301; Alfares AA et al. Genet. Med., 2015 Nov;17:880-8; Norrish G et al. Circulation, 2019 Jul;140:184-192). Furthermore, two different variants impacting the same amino acid, p.G87E and p.G87W, have also been reported in hypertrophic cardiomyopathy (HCM) cohorts with limited clinical information provided (Zou Y et al. Mol. Biol. Rep., 2013 Jun;40:3969-76; Wang J et al. Eur. J. Heart Fail., 2014 Sep;16:950-7). In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at